Company intelligence / Profile preview

Zhongshan Kangfang Biomedical

Zhongshan, Guangdong Sheng, Chinaakesobio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Akeso has developed one of China's most diversified innovative antibody pipelines with over 50 candidates, including three approved drugs. Its lead product Ivonescimab outperformed Pembrolizumab in a phase 3 head-to-head trial for non-small cell lung cancer and was approved in China in May 2024. The company has multiple late-stage clinical trials ongoing.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugatemRNA-based drugsCell therapy
Industry: Biotech

Drug pipeline

2 assets

inucimab

Phase 2

Indications: Metabolic diseases

1 more asset in the full pipeline.

Request access →

Partnerships

Summit TherapeuticsGE HealthcareChina Biopharmaceuticals

Beyond the preview

Go deeper on Zhongshan Kangfang Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhongshan Kangfang Biomedical.

Explore the full profile